In contrast to previous observations, Felsberg et al. reported a relatively low percentage of 11% MGMT promoter methylation changes in relapse, of which they say only 6% can be considered as true changes, since their loss or decrease of MGMT promoter methylation at tumor recurrence could not be explained by a low tumor cell content of the respective tissue samples [49]. This evidence concerns the gene MGMT and neoplasm.